Researchers at NYU Grossman School of Medicine have found some of the strongest evidence yet linking lupus flare-ups to a specific imbalance in gut bacteria — a discovery that could point toward an entirely new class of treatments for the disease. The study, published in the Annals of Rheumatic Diseases, found that bacterial blooms of Ruminococcus gnavus in the gut occurred simultaneously with disease flare-ups in a subset of lupus patients tracked over four years.
In the study of 16 women with systemic lupus erythematosus, five experienced R. gnavus blooms that coincided with active flares. Four of those patients had lupus nephritis — the severe, kidney-targeting form of the disease — while the fifth had multi-joint inflammation. The research identified 34 genes already linked to the bacterium’s growth in people with inflammation, and found that immune antibodies reacted strongly to specific lipoglycan molecules on the bacterial wall — molecules found in lupus patients but not in healthy individuals.
The findings suggest a biological mechanism: R. gnavus blooms may weaken the gut wall, allowing bacterial material to leak into the bloodstream and trigger the runaway immune responses that define lupus. If confirmed at scale, this could open the door to treatments based on probiotics, dietary interventions, or targeted antibacterial agents — approaches that would be less toxic than the broad immunosuppressants currently used to manage the disease.
Featured Experts

Katsuo Kurabayashi, PhD
Colton Consortium Member
Department Chair, Mechanical and Aerospace Engineering, NYU Tandon School of Engineering
Carla R. Nowosad, PhD
Colton Consortium Member
Assistant Professor, Department of Pathology, NYU Grossman School of Medicine / NYU Langone Health
Jun Wang, PhD
Colton Consortium Member
Associate Professor, Department of Pathology, NYU Grossman School of Medicine / NYU Langone HealthFeatured Projects

The Role and Mechanism of Aberrant Dendritic Cell Function in Autoimmunity
Identifying a novel molecular regulator of tolerogenic dendritic cell function, this project uncovers how its loss triggers spontaneous multiorgan autoimmunity and exacerbates lupus — revealing a clinically relevant pathway in immune tolerance.

Utilizing RNA Replicons as Immune Modulators for Systemic Lupus Erythematosus
A self-replicating RNA platform delivers anti-inflammatory cytokines directly to the airways, offering targeted local immune suppression without systemic toxicity — a mechanistically distinct approach to treating lupus lung disease.
Featured Publications
The multiple roles of gamma interferon in intraepithelial T cell-villous enterocyte interactions in active celiac disease
The subfornical organ is a nucleus for gut-derived T cells that regulate behaviour
Related News

What a "Silenced" Chromosome Can Tell Us About Autoimmunity
Penn Colton Center researcher Montserrat Anguera reveals how B cells maintain X chromosome inactivation, and how its breakdown drives lupus, offering new insight into female-biased autoimmune disease and treatment targets.

Yale News Spotlights the Colton Center as a Key Driver of Autoimmune Innovation at Yale Ventures
A Yale News feature on Yale Ventures' five accelerator funds highlights the Colton Center for Autoimmunity's growing role in translating autoimmune research into startups, licenses, and real-world therapies.

Yale Researchers Use Machine Learning Tool to Improve Personalized Immunotherapy Design
A Colton-supported Yale study has produced ImmunoStruct, a machine learning model that improves personalized cancer vaccine design by incorporating the 3D structure of immune-activating peptides — now licensed to a Yale spinout.